問卷

TPIDB > Search Result

Search Result

篩選

List

1449Cases

2021-08-01 - 2027-02-28

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-04-01 - 2026-05-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2022-02-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-09-30 - 2028-08-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2026-04-17 - 2028-08-02

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2021-11-17 - 2030-07-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-11-15 - 2028-11-26

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-12-26 - 2026-05-14

Phase III

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2019-09-01 - 2027-12-31

Phase III

Active
Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C≤2%) (BeneGene-2)
  • Condition/Disease

    The study compared the differences between the trial drug before and after infusion, and evaluated the non-inferiority of the annual average bleeding rate (ABR) of total bleeding events (treatment-free and treatment-free) from week 12 to month 15 compared with standard of care (SOC) FIX prophylactic alternative therapy.

  • Test Drug

    injection

Participate Sites
5Sites

Recruiting5Sites

2022-09-01 - 2028-12-31

Phase III

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
4Sites

Recruiting4Sites